ITRM20010408A1 - Mini-anticorpo umano citotossico per cellule tumorali che esprimono il recettore erbb2. - Google Patents

Mini-anticorpo umano citotossico per cellule tumorali che esprimono il recettore erbb2.

Info

Publication number
ITRM20010408A1
ITRM20010408A1 IT2001RM000408A ITRM20010408A ITRM20010408A1 IT RM20010408 A1 ITRM20010408 A1 IT RM20010408A1 IT 2001RM000408 A IT2001RM000408 A IT 2001RM000408A IT RM20010408 A ITRM20010408 A IT RM20010408A IT RM20010408 A1 ITRM20010408 A1 IT RM20010408A1
Authority
IT
Italy
Prior art keywords
antibody
express
cancer cells
erbb2 receptor
erbb2
Prior art date
Application number
IT2001RM000408A
Other languages
English (en)
Inventor
Alessio Giuseppe D
Renata Piccoli
Lorenzo Claudia De
Donald Balfour Palmer
Mary Alice Ritter
Original Assignee
Univ Napoli Federico Ii
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Napoli Federico Ii filed Critical Univ Napoli Federico Ii
Priority to IT2001RM000408A priority Critical patent/ITRM20010408A1/it
Publication of ITRM20010408A0 publication Critical patent/ITRM20010408A0/it
Priority to SI200230870T priority patent/SI1432737T1/sl
Priority to EP02784853A priority patent/EP1432737B1/en
Priority to CA002453435A priority patent/CA2453435A1/en
Priority to NZ531035A priority patent/NZ531035A/en
Priority to PCT/EP2002/007671 priority patent/WO2003006509A2/en
Priority to US10/483,803 priority patent/US7585952B2/en
Priority to ES02784853T priority patent/ES2334895T3/es
Priority to PT02784853T priority patent/PT1432737E/pt
Priority to AT02784853T priority patent/ATE445646T1/de
Priority to DE60234041T priority patent/DE60234041D1/de
Priority to DK02784853.0T priority patent/DK1432737T3/da
Publication of ITRM20010408A1 publication Critical patent/ITRM20010408A1/it
Priority to ZA200401044A priority patent/ZA200401044B/en
Priority to US12/506,152 priority patent/US8227585B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
IT2001RM000408A 2001-07-10 2001-07-10 Mini-anticorpo umano citotossico per cellule tumorali che esprimono il recettore erbb2. ITRM20010408A1 (it)

Priority Applications (14)

Application Number Priority Date Filing Date Title
IT2001RM000408A ITRM20010408A1 (it) 2001-07-10 2001-07-10 Mini-anticorpo umano citotossico per cellule tumorali che esprimono il recettore erbb2.
DK02784853.0T DK1432737T3 (da) 2001-07-10 2002-07-10 Humant mini-antistof cytotoxisk for tumorceller der udtrykker ERBB2-receptoren
US10/483,803 US7585952B2 (en) 2001-07-10 2002-07-10 Human mini-antibody cytotoxic for tumor cells which express the ErbB2 receptor
PT02784853T PT1432737E (pt) 2001-07-10 2002-07-10 Mini-anticorpo humano citotóxico para células tumorais que expressam o receptor erbb2
CA002453435A CA2453435A1 (en) 2001-07-10 2002-07-10 Human mini-antibody cytotoxic for tumor cells which express the erbb2 receptor
NZ531035A NZ531035A (en) 2001-07-10 2002-07-10 Human mini-antibody cytotoxic for tumor cells which express the ErbB2 receptor
PCT/EP2002/007671 WO2003006509A2 (en) 2001-07-10 2002-07-10 Human mini-antibody cytotoxic for tumor cells which express the erbb2 receptor
SI200230870T SI1432737T1 (sl) 2001-07-10 2002-07-10 Humano mini-protitelo, citotoksično za tumorske celice, ki izražajo ERBB2 receptor
ES02784853T ES2334895T3 (es) 2001-07-10 2002-07-10 Mini-anticuerpo humano citotoxico para las celulas tumorales que expresan el receptor erbb2.
EP02784853A EP1432737B1 (en) 2001-07-10 2002-07-10 Human mini-antibody cytotoxic for tumor cells which express the erbb2 receptor
AT02784853T ATE445646T1 (de) 2001-07-10 2002-07-10 Humaner miniantikörper zytotoxisch für tumorzellen die den erbb2 rezeptor exprimieren
DE60234041T DE60234041D1 (de) 2001-07-10 2002-07-10 Humaner miniantikörper zytotoxisch für tumorzellen die den erbb2 rezeptor exprimieren
ZA200401044A ZA200401044B (en) 2001-07-10 2004-02-09 Human mini-antibody cytotoxic for tumor cells which express the ErbB2 receptor.
US12/506,152 US8227585B2 (en) 2001-07-10 2009-07-20 Human mini-antibody cytotoxic for tumor cells which express the ERBB2 receptor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2001RM000408A ITRM20010408A1 (it) 2001-07-10 2001-07-10 Mini-anticorpo umano citotossico per cellule tumorali che esprimono il recettore erbb2.

Publications (2)

Publication Number Publication Date
ITRM20010408A0 ITRM20010408A0 (it) 2001-07-10
ITRM20010408A1 true ITRM20010408A1 (it) 2003-01-10

Family

ID=11455653

Family Applications (1)

Application Number Title Priority Date Filing Date
IT2001RM000408A ITRM20010408A1 (it) 2001-07-10 2001-07-10 Mini-anticorpo umano citotossico per cellule tumorali che esprimono il recettore erbb2.

Country Status (13)

Country Link
US (2) US7585952B2 (it)
EP (1) EP1432737B1 (it)
AT (1) ATE445646T1 (it)
CA (1) CA2453435A1 (it)
DE (1) DE60234041D1 (it)
DK (1) DK1432737T3 (it)
ES (1) ES2334895T3 (it)
IT (1) ITRM20010408A1 (it)
NZ (1) NZ531035A (it)
PT (1) PT1432737E (it)
SI (1) SI1432737T1 (it)
WO (1) WO2003006509A2 (it)
ZA (1) ZA200401044B (it)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITFI20010114A1 (it) * 2001-06-22 2002-12-22 Univ Firenze Glicopeptidi,loro preparazione e loro uso nella diagnosi o nel trattamento terapeutico della sclerosi multipla
CN101141981A (zh) 2005-01-21 2008-03-12 健泰科生物技术公司 Her抗体的固定剂量给药
DK1850874T3 (da) 2005-02-23 2013-11-11 Genentech Inc Forlængelse af tid til sygdomsprogression eller overlevelse for ovariecancer ved anvendelse af pertuzumab
US20100015661A1 (en) * 2006-04-21 2010-01-21 Mab-Factory Gmbh Antibody-rnase-conjugate
LT2511301T (lt) * 2006-08-04 2018-04-10 Medimmune Limited Žmogaus antikūnas prieš erbb2
EP2132573B1 (en) 2007-03-02 2014-04-23 Genentech, Inc. Predicting response to a her dimerisation inhbitor based on low her3 expression
PL2171090T3 (pl) 2007-06-08 2013-09-30 Genentech Inc Markery ekspresji genów odporności guza na leczenie hamujące HER2
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
TWI461211B (zh) 2009-03-20 2014-11-21 Genentech Inc 抗－ｈｅｒ抗體
SG176073A1 (en) 2009-05-29 2011-12-29 Hoffmann La Roche Modulators for her2 signaling in her2 expressing patients with gastric cancer
US9556249B2 (en) 2010-02-18 2017-01-31 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
CA3188287A1 (en) 2010-03-26 2011-09-29 Memorial Sloan-Kettering Cancer Center Antibodies to muc16 and methods of use thereof
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
EP2643353A1 (en) 2010-11-24 2013-10-02 Novartis AG Multispecific molecules
US20120148559A1 (en) 2010-12-01 2012-06-14 Board Of Regents The University Of Texas System Compositions and method for deimmunization of proteins
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
EP2744824A1 (en) 2011-08-17 2014-06-25 F.Hoffmann-La Roche Ag Neuregulin antibodies and uses thereof
WO2013063229A1 (en) 2011-10-25 2013-05-02 The Regents Of The University Of Michigan Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
CA2857114A1 (en) 2011-11-30 2013-06-06 Genentech, Inc. Erbb3 mutations in cancer
US9376715B2 (en) 2011-12-09 2016-06-28 Roche Molecular Systems, Inc Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
EP2831115A1 (en) 2012-03-27 2015-02-04 F. Hoffmann-La Roche AG Diagnosis and treatments relating to her3 inhibitors
JP6998646B2 (ja) 2012-11-30 2022-02-04 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｐｄ－ｌ１阻害剤併用療法を必要とする患者の同定
WO2014200891A1 (en) * 2013-06-11 2014-12-18 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTEMENT OF HEALTH & HUMAN SERVICES Her2-specific monoclonal antibodies and conjugates thereof
ES2711558T3 (es) * 2013-08-26 2019-05-06 Health Research Inc Método de prevención y/o tratamiento de cánceres ErbB2-positivos
SG11201608192SA (en) 2014-04-11 2016-10-28 Medimmune Llc Bispecific her2 antibodies
US10647768B2 (en) 2014-05-29 2020-05-12 Macrogenics, Inc. Multi-chain polypeptide-containing tri-specific binding molecules
TWI695011B (zh) 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 抗ｈｅｒ２表位之單株抗體及其使用之方法
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
CN107075490A (zh) 2014-08-20 2017-08-18 健康研究公司 用于预防和/或治疗erbb1阳性癌症的方法
UY36316A (es) 2014-09-26 2016-04-29 Macrogenics Inc Diacuerpos monovalentes biespecíficos que son capaces de unir cd19 y cd3, y usos de los mismos
CN107667120B (zh) 2015-03-17 2022-03-08 纪念斯隆-凯特林癌症中心 抗muc16抗体及其应用
SG10201601719RA (en) 2016-03-04 2017-10-30 Agency Science Tech & Res Anti-LAG-3 Antibodies
EP3454863A1 (en) 2016-05-10 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
SG10201603721TA (en) 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07309780A (ja) * 1994-03-02 1995-11-28 N Bii T Kk 抗癌剤
US5795961A (en) * 1995-02-14 1998-08-18 Ludwig Institute For Cancer Research Recombinant human anti-Lewis b antibodies
GB9805660D0 (en) * 1998-03-18 1998-05-13 Unichema Chemie Bv Improvements in and relating to fatty acid metabolism
US6135941A (en) 1998-03-27 2000-10-24 Incyte Pharmaceuticals, Inc. Human immune system associated molecules
US6794128B2 (en) 1998-04-24 2004-09-21 The Regents Of The University Of California Methods of selecting internalizing antibodies
US7244826B1 (en) * 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
GB9809280D0 (en) * 1998-04-30 1998-07-01 Rpms Technology Ltd Immunosupression
AU6841300A (en) * 1999-08-26 2001-03-19 Morphosys Ag Human antibodies or fragments thereof binding to hla-cw6
WO2001027279A1 (en) * 1999-10-12 2001-04-19 Cambridge Antibody Technology Human anti-adipocyte monoclonal antibodies and their use

Also Published As

Publication number Publication date
NZ531035A (en) 2005-04-29
US7585952B2 (en) 2009-09-08
CA2453435A1 (en) 2003-01-23
ITRM20010408A0 (it) 2001-07-10
PT1432737E (pt) 2010-02-17
EP1432737A2 (en) 2004-06-30
EP1432737B1 (en) 2009-10-14
US20100173978A1 (en) 2010-07-08
ES2334895T3 (es) 2010-03-17
WO2003006509A2 (en) 2003-01-23
ATE445646T1 (de) 2009-10-15
US20070258985A1 (en) 2007-11-08
SI1432737T1 (sl) 2010-02-26
WO2003006509A3 (en) 2003-11-20
US8227585B2 (en) 2012-07-24
ZA200401044B (en) 2004-10-22
DE60234041D1 (de) 2009-11-26
DK1432737T3 (da) 2010-02-08

Similar Documents

Publication Publication Date Title
ITRM20010408A1 (it) Mini-anticorpo umano citotossico per cellule tumorali che esprimono il recettore erbb2.
RS80704A (en) ANTI- av?6.ANTIBODIES
MX2007000103A (es) Bibliotecas de anticuerpos universales.
BE2016C015I2 (it)
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
ZA200508389B (en) Humanized antibodies to interferon alpha receptor-1(IFNAR-1)
TR200102733T2 (tr) IL-18 kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri
MX2009003838A (es) Anticuerpos anti-cd20 y metodos de uso.
NZ600584A (en) Anti-il 17a/il-17f cross-reactive antibodies and methods of use thereof
WO2004029092A3 (fr) Anticorps pour adcc et induisant la production de cytokines.
IL129299A0 (en) Monoclonal antibodies antigens and diagnosis of malignant diseases
WO2006113546A3 (en) Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
RS52889B (sr) Terapijsko humano anti-il-1r1 monoklonsko antitelo
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
IN2009KN02655A (it)
SG151284A1 (en) Antibodies against ccr5 and uses thereof
GEP20074222B (en) Antibodies to cd40
US20080038256A1 (en) Anti-hgf/sf humanized antibody and method for the preparation thereof
MX2009001110A (es) Anticuerpos monoclonales anti-il-6 y usos de los mismos.
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
RS20100555A (en) HUMAN ANTI-NGF NEUTRAL ANTIBODIES AS SELECTIVE NGF SIGNAL ROUTE INHIBITORS
NZ597466A (en) Recombinant anti-epidermal growth factor receptor antibody compositions
TW200510459A (en) RG1 antibodies and uses thereof
TW200738748A (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
MX2007002675A (es) Antagonistas anti-beta7 humanizados y usos para los mismos.